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Purpose of the study
Short-term antiretroviral therapy (START) consisting of
2 NRTIs and a ritonavir boosted PI is widely used in
pregnancy. Resistance is rarely detected using popula-
tion based sequencing. The aim of this study was to
determine whether minority M184V variants emerge
with 3TC/FTC containing START regimens in preg-
nancy and if so whether this impacted upon future
treatment outcomes.
Methods
Multi-centre study. An allele-specific real time PCR
(ASPCR), optimized for subtypes B, C and AG, was
used to detect minority M184V variants. Participants
1Guy’s & St Thomas’ NHS Foundation Trust, Department of GUM & HIV,
London, UK
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Table 1
M184V mutants N=7 WT N=11
Median Age, yrs (range) 30 (26.5-37) 34 (21-38)
African origin 7 (100%) 7 (64%)
European origin 0 2 (18%)
Caribbean origin 0 1 (9%)
South American origin 0 1 (9%)
Median gestation at START initiation, completed weeks (range) 22 (19-26) 21 (15-29)
Median duration START, days (range) 115 (87-132) 121 (68-151)
Virological suppression at delivery 6 (86%) (other VL 57c/ml) 11 (100%)
Subtype B 1 (14%) 4 (36%)
Subtype C 5 (72%) 1 (9%)
Subtype AG 1 (14%) 6 (55%)
Previous ART 2/7 (29%) 3/11 (27%)
Previous ART regimens ZDVm, CBV/LPVr ZDVm, CBV/nelfinavir, CBV/nelfinavir
Population based sequencing performed 7/7 (100%) 10/11 (91%) (1 failed)
WT on population based sequencing 7/7 10/10
Number of Lopinavir TDM performed 6/7 (86%) 5/11 (45%)
Median Lopinavir concentration (µg/L) (range) 4446 (2791-7551) 2991 (2023-7782)
Subsequent ART 4/7 (57%) 3/11 (27%)
Virological suppression with subsequent ART 4/4 (100%) 2/3 (67%) (1 stopped after a few weeks)
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transmission (PMTCT). All received standard dose
LPVr. Plasma samples were tested pre and post treat-
ment. Routine population based sequencing was also
performed.
Summary of results
ASPCR failed in 13/31 (42%) women. Among the
remaining 18, 11(61%) were wild type (WT) and 7
(22.5%) had minority M184V sequences (range of detec-
tion 0.5 to 14%). All samples were WT with population
based sequencing. ASPCR failed to amplify from pre-
treatment samples in 4/7 women with minority M184V
and was WT in 3. Table 1 compares women with and
without M184V mutants detected by ASPCR. Therapeu-
tic drug monitoring (TDM) was performed in a subset.
Conclusions
M184V mutants were detected after LPVr based START
for PMTCT in 22.5% women. No difference in prior
ART, START duration, drug concentration or virologi-
cal suppression was observed. The presence of minority
M184V variants post-partum did not affect future treat-
ment success. The possible association with HIV-1 sub-
type C requires further evaluation but clade effect on
the development of resistance has been reported follow-
ing intra-partum nevirapine.
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